A major contributor to this article appears to have a close connection with its subject.(August 2020) |
Chandler Park | |
---|---|
Education | Biomedical engineering B.S. at (University of Illinois at Urbana-Champaign) Medical Doctorate M.D. at (University of Louisville School of Medicine) biophysics MSc (University of Louisville Graduate School) Transitional surgery internship at Cleveland Clinic Foundation Health Systems diagnostic radiology and internal medicine residency at Indiana University School of Medicine |
Occupation(s) | Physician, clinical researcher, medical writer |
Chandler Park is an American physician, medical journalist, and clinical researcher. [1] In June 2021, his cancer research was published in prominent medical journals including the New England Journal of Medicine [2] and Journal of Clinical Oncology. [3] Park also contributes regularly as an expert physician for popular newspapers and magazines such as Newsweek , [4] Reader's Digest , [5] [6] [7] U.S. News & World Report , [8] The Exponent-Telegram , [9] College of St. Scholastica , [10] and Medscape [11] and writes medical news for Doximity. [12] [13]
Park is a clinical professor that teaches biochemistry, physiology, hematology, and medical oncology at the University of Louisville School of Medicine. [14] He also works as an advisory Dean at the University of Louisville School of Medicine and plays a vital role in the transition into medical school and the development into a physician. [15] Park was selected as a teaching faculty to provide new cancer information at American Society of Clinical Oncology. [16] In February 2019, he helped develop the continuing medical education course titled 2019 Breast and Gynecologic Cancers for American Society of Clinical Oncology [17] and published his continuing medical education course in Anticancer Therapeutics, Research, and Supportive Care. [18] In February 2020, he also helped develop a new continuing medical education online course for cancer physicians in America to update them on new cancer information in Hematologic Malignancies and Blood Cancers. [19] In June 2020, he was interviewed to discuss CAR-T Cell and provided information on upcoming treatments for CAR-T cell. [20]
Park is also one of the contributing authors of the book, Lung Cancer: Standards of Care [21] that discusses diagnosis and treatment of lung cancers released in December 2020. [22] Park was also interviewed by Targeted Oncology on Kidney Cancer Treatments in February 2021. [23]
In 2020, Park was selected as the President of the Kentucky Society of Clinical Oncology. [24] The Kentucky Society of Clinical Oncology is the state affiliate of American Society of Clinical Oncology, American Society of Hematology, and National Cancer Institute.
He has been interviewed by leading cancer media digital media including Cure Magazine, [25] [26] Targeted Oncology, [27] [28] Urology Times, [29] and OncLive [30] [31] [32] in 2023.
Park writes medical columns for Medscape [33] and Doximity Op(m)ed. [34] He writes articles on medical education and cancer news. [35] His medical education writings include The Hidden Curriculum: How to Avoid Being Labeled a Problem Resident. [36] He has also written cancer news at the American Society of Clinical Oncology and American Society of Hematology annual meetings, [37] [38] [39] and has volunteered on the editorial board of Journal of Hospital Practice and helps select cancer journal articles for hospital physicians. [40] Park is the founder of Cancervisit a company dedicated to helping cancer patients and their families. [41] In April 2020, Park was interviewed by the American College of Physicians on ways medical students can prepare for residency training. [42]
Park also provides video medical updates for physicians on IMDb [43] and YouTube. [44] He has written cancer updates in kidney cancer with Toni Choueiri, [45] prostate cancer with Neeraj Agarwal, [46] and Bladder Cancer with Petros Grivas [47]
Park received a Bachelor of Science degree in Biomedical Engineering and Biochemistry from University of Illinois at Urbana-Champaign and his Doctor of Medicine degree from the University of Louisville School of Medicine. He also acquired medical science research training at the University of Louisville in Louisville, Kentucky and received a master's degree in science in biophysics.
After his medical school and graduate school research training, Park served his surgery transitional internship at Cleveland Clinic Foundation Health Systems. Next, he did his residency training in diagnostic radiology and internal medicine at IU Medical Center. Afterwards he finished subspecialist medical training in Hematology and Oncology at WVU Cancer Institute and received additional medical training as a visiting fellow at University of Pittsburgh in cancer immunotherapy. [48]
He is a practicing cancer physician at Norton Cancer Institute and a physician member of the molecular tumor board at the University of Kentucky Markey Cancer Center. [49] Park is triple-board-certified in internal medicine, hematology and oncology. [50]
Park has participated in multiple cancer clinical trials in lung, melanoma, thyroid, and bone marrow transplant. He has been nationally recognized as an exceptional doctor by his physician colleagues and was given an honorary title as a distinguished fellow of the American College of Physicians (FACP) for providing outstanding patient care and significant medical research contributions. [51]
Park has written cancer papers about PET/CT and regional brain metabolic changes associated with depression in metastatic breast cancer, [52] sorafenib and thyroid cancer, [53] pemetrexed-based chemotherapy in lung cancer, [54] atypical neurolymphomatosis, [55] metformin use and allogenic stem cell transplant, [56] and decreased cancer rates. [57]
Park's medical research also included an MRI study that used viscoelastic pads to improve patient care during MRI studies. His research group developed the patented viscoelastic pads used by many of the current MRI tables. [58] The viscoelastic pads decrease ischemia, pain, and discomfort for patients undergoing MRI studies. His MRI research led to improved quality of the MRI imaging studies to improve patient care, [59] He has also studied the effect of nicotine on bone arteriole blood flow. [60]
He also volunteers on the editorial board of Journal of Hospital Practice and helps select cancer journal articles for hospital physicians. [61]
After his landmark MRI study was published, Park has been a live public speaker at large medical society meetings including American Society for Therapeutic Radiology and Oncology, and Radiological Society of North America. [62] He was invited as a speaker to discuss "Designing Continuing Professional Development that improves patients care: Insights from a Practicing Oncologist" at the annual Alliance for Continuing Education meeting in Orlando, Florida. [63] In July 2018, he was interviewed by healthcare industry leading magazine Managed Health Care Executive on Five Ways Health Execs Can improve Lymphoma Treatment. [64]
In January 2020, he gave a live oral presentation to the Alliance of Continuing Medical Education for Healthcare Providers to improve cancer care by medical oncologists by discussing the importance of shared decision making with physicians, patients, nurses, patients' families, pharmacists, and the entire clinical care team. [65] He also co-hosted a medical education program for the Society for Immunotherapy of Cancer that discussed Advances in Cancer Immunotherapy on December 10, 2020. [66]
Park has been chosen as a Castle Connolly Top Doctor [67] in Cancer by his physician peers in 2019, [68] 2020, [69] and 2021. [70] In 2021, Park was recognized as one of the 3 best oncologists in Louisville, Kentucky by Three Best Rated. [71]
Park has also been recognized by the American Registry company with patient care awards in Patient's choice [72] and Compassionate Doctor. [73] In June 2020, he received the 5 year Patient's Choice award as one of Kentucky's Favorite Physicians [74] and top 1% of America's Most Honored Doctors. [75]
Nicholas J. Vogelzang was a medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN). He serves as medical director of the Research Executive Committee and Associate Chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research. His research interests include clinical trials for genitourinary malignancies and mesothelioma.
Harry F. Bisel, M.D. (1918–1994) was an American oncologist. With Fred Ansfield, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane Wright, was one of the founding members of the American Society of Clinical Oncology (ASCO). This group of pioneering doctors, through the formation of ASCO, is largely credited with the development of modern American clinical oncology. In 1964, Bisel was elected the first president of ASCO. He was active in the American Cancer Society and was a consultant to the National Cancer Institute. Bisel was a founding member of the American Society of Preventive Oncology as well as the American Association for Cancer Education.
The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.
Oncology is a branch of medicine that deals with the study, treatment, diagnosis, and prevention of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass". Oncology is concerned with:
Tower Cancer Research Foundation (TCRF) is a 501(c)(3) non-profit organization dedicated to clinical research, patient support and community education. It was established in 1996 in Beverly Hills, California.
Texas Oncology is a network of 460+ physicians and oncology specialists who provide advanced treatment options to cancer patients in underserved rural and urban communities throughout Texas, with one office in New Mexico and one in Oklahoma. More than 68,000 patients are treated within the Texas Oncology network annually.
Wolfram Samlowski is an American medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN) and a member of the Research Developmental Therapeutics and Genitourinary Committees for US Oncology. His research interests include translational research and development of novel cancer immunotherapy agents, translational drug development as well as gene therapy. His clinical interests are in developing more effective treatments for advanced stages of melanoma and non-melanoma skin cancers, and renal cancer.
High-dose chemotherapy and bone marrow transplant (HDC/BMT), also high-dose chemotherapy with autologous bone marrow transplant, was an ineffective treatment regimen for metastatic breast cancer, and later high-risk breast cancer, that was considered promising during the 1980s and 1990s. With an overall idea that more is better, this process involved taking cells from the person's bone marrow to store in a lab, then to give such high doses of chemotherapy drugs that the remaining bone marrow was destroyed, and then to inject the cells taken earlier back into the body as replacement. It was ultimately determined to be no more effective than normal treatment, and to have significantly higher side effects, including treatment-related death.
Pramod Kumar Julka, is an Indian cancer specialist (oncologist), medical educationist and writer, known for performing the first peripheral blood stem cell transplant following high dose chemotherapy in Metastatic Breast Cancer in India. He was honoured by the Government of India, in 2013, by bestowing on him the Padma Shri, the fourth highest civilian award, for his contributions to the fields of medicine and medical education. The American Society of Clinical Oncology (ASCO) has awarded him by bestowing on him the honorary membership.
Walter "Wally" J. Curran, Jr. is an American radiation oncologist specializing in the treatment of malignant brain tumors and locally advanced lung cancer.
Thomas E. Hutson is an American medical oncologist and cancer researcher based in Dallas, Texas. He is the director of Genitourinary Oncology Program and co-director of the Urologic Cancer Research and Treatment Center at Baylor University Medical Center. He is a Professor of Medicine at the Texas A&M Health Science Center College of Medicine and serves as a chair of Genitourinary Research for US Oncology and McKesson.
Sandra M. Swain is an American oncologist, breast cancer specialist and clinical translational researcher. She is currently a professor of Medicine at the Georgetown University School of Medicine and the Associate Dean for Research Development at Georgetown University Medical Center (GUMC) and MedStar Health as well as an adjunct professor of Medicine at the F. Edward Hébert School of Medicine of the Uniformed Services University of Health Sciences. She is also a past President of the American Society of Clinical Oncology (ASCO), serving from 2012 through 2013.
Edith Peterson Mitchell was a retired Brigadier general of the United States Air Force and an oncologist. She was clinical professor of medicine and medical oncology at Thomas Jefferson University. In 2015, she became the president of the National Medical Association.
Everett E. Vokes is an American oncologist. He is the John E. Ultmann Professor, chair of the Department of Medicine, and physician-in-chief at the University of Chicago Medical Center. In this role, he pioneered the combination radiation and chemotherapy as first-line treatment for head and neck cancer.
Lori Jo Pierce is an American radiation oncologist and 57th President of the American Society of Clinical Oncology. She is a Full Professor and Vice Provost for Academic and Faculty Affairs at the University of Michigan. Her research focuses on the use of radiotherapy in the multi-modality treatment of breast cancer, with emphasis on intensity modulated radiotherapy in node positive breast cancer, the use of radiosensitizing agents, and the outcomes of women treated with radiation for breast cancer who are carriers of a BRCA1/2 breast cancer susceptibility gene.
Stephanie Lynn Schutt Graff is an American breast medical oncologist. She is the Director of Breast Oncology at the Lifespan Cancer Institute and an Assistant Professor of Medicine at Alpert Medical School. Previously she was the Director of both the Breast Program and Clinical Research at Sarah Cannon Research Institute at HCA Midwest Health at Sarah Cannon Research Institute and Associate Director of the Breast Cancer Research Program at Sarah Cannon Research Institute.
Maura Lianne Gillison is an American medical oncologist and molecular epidemiologist. She is credited as the first investigator to establish a connection between HPV and oral cancer.
Elizabeth R. Plimack is an American medical oncologist. She is a professor in the Department of Hematology/Oncology and Chief of the Division of Genitourinary Medical Oncology at the Fox Chase Cancer Center. In these roles, she researches the treatment of genitourinary malignancies with a focus on bladder and kidney cancers.
Patrick J. Loehrer is an American oncologist who is Indiana University Distinguished Professor, Joseph W. and Jackie J. Cusick Professor in Oncology, Professor of medicine, Indiana University School of Medicine; Director emeritus, Indiana University Melvin and Bren Simon Comprehensive Cancer Center.
Tara Olive Henderson is an American pediatric oncologist. As the Arthur and Marian Edelstein Professor in the Department of Pediatrics, she is also the Director of the Childhood Cancer Survivor Center, Director of Survivorship at the University of Chicago Comprehensive Cancer Center, and chief of Pediatric Hematology and Oncology at the University of Chicago.
{{cite web}}
: CS1 maint: numeric names: authors list (link)